Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 56

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 56
---
 may include, without limitation, risks related to general economic and business conditions; our ability to continue as a going concern; our ability to obtain financing necessary to operate our business; our ability to consummate the Share Exchange Agreement with LipoVation (as described below); our ability to recruit and retain qualified personnel; our ability to manage any future growth; our ability to research and successfully develop our planned products; our ability to successfully complete potential acquisitions and collaborative arrangements; and other factors including those set forth below under the caption “ Risk Factors.”

This Prospectus also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other industry data. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified the statistical and other industry data generated by independent parties and contained in this Prospectus. In addition, projections, assumptions, and estimates of our future performance and the future performance of the industries in which we operate are necessarily subject to a high degree of uncertainty and risk due to a variety of factors.

<div align='center'>30

USE OF PROCEEDS</div>

Our Primary Offering is being made on a self-underwritten
basis, and there is no minimum number of Units that must be sold in the Primary Offering

We estimate that the net proceeds from the sale
of the Units by the Company in the Primary Offering will be approximately $4.4 million (assuming the sale of all securities offered hereby,
at the fixed public offering price of $3.20 per Unit, assuming no exercise of the IPO Warrants issued in connection with this offering),
after deducting the estimated offering expenses payable by us. We cannot predict when or if any of the Units will be sold.

We are offering the 1,562,500 Units on a best-efforts
basis such that the funds received from an investment in this Offering will be available to us immediately for use. Funds will not be
placed in an escrow account and there is no minimum investment that needs to be reached before the funds are available for our use.

We currently anticipate allocating up to 80%
of the net proceeds to research and development activities, including manufacturing, regulatory submissions, and clinical development
for our lead product candidates. The remaining funds will be used for general corporate purposes, including personnel, professional services,
and administrative costs.

Estimated use of proceeds, assuming $600,000 offering expenses irrespective
of the amount sold.

| If 390,625 Units